Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting
SAN DIEGO, April 14, 2011 /PRNewswire/ -- New results from the largest multicenter clinical trial for heart transplant patients will be released this week at the International Society for Heart & Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions in San Diego. Results show clinical benefit for the use of Everolimus in heart transplant patients.
The trial includes 721 randomized patients at 67 medical centers spanning 5 continents. The research compared the efficacy of anti-rejection therapy Everolimus with the current standard of care Mycophenolate Mofetil (MMF).
Research to be presented at the ISHLT Meeting includes:
- Everolimus-Based Immunosuppression Versus Conventional Treatment in Long-Term Heart Transplanted Patients: Three Years Results of a Prospective Randomized Trial (abstract 2) is a featured abstract during the Thursday morning Opening Plenary Session at 9:30am PDT.
- Reduction of Cardiac Allograft Vasculopathy with Everolimus over Mycophenolate Mofetil: Intravascular Ultrasound Results of a Randomized Multicenter Trial (abstract 52) will be presented Thursday during an afternoon symposium at 2:00pm PDT.
- Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis (abstract 55) will be discussed during the same Thursday symposium at 2:45pm PDT.
- Heart Transplant Recipients Treated with Everolimus Have Less Increase in Intimal Thickness vs MMF, Irrespective of Lipid Values (abstract 57), will also be presented on Thursday afternoon, 3:15pm PDT.
Intravascular Ultrasound Results
One study, specifically looking at intravascular ultrasound (IVUS) results, showed a robust benefit with Everolimus relative to Mycophenolate Mofetil (MMF) by IVUS at the